Biohaven Pharmaceutical Holding Company Ltd. Stock

$39.42

3.52% today

NYSE, Sep 16, 08:18 pm CET

ISIN

VGG111961055

Symbol

BHVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$38.08

-8.95 19.03% 5Y

NYSE, Closing price Fri, Sep 13 2024

+2.33 6.52%

ISIN

VGG111961055

Symbol

BHVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$3.60b
Enterprise Value	$3.19b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	9.16
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-781.27m
Free Cash Flow (TTM) Free Cash Flow	$-485.24m
Cash position	$437.10m
EPS (TTM) EPS	$-9.16
P/E forward	negative
Short interest	12.24%

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Get Started for Free Today

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

12x Buy

100%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter Annually

Assets

Jun '24
Current assets	511 511
Cash	437 437
Claims	7.52 7.52
Inventories	- -
Other current assets Other current assets Current assets	67 67

Fixed assets	71 71
Property, plant and equipment	49 49
Financial assets	3.02 3.02
Intangible Assets	20 20
Other fixed assets Other assets Fixed assets	- -


Total Assets	583 583

Liabilities

Jun '24
Equity	384 384

Debt capital	199 199
Current liabilities	156 156
Non-current liabilities	43 43


Total Capital	583 583

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Neutral

PRNewsWire

●

about one month ago

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform advancing multiple new targets and reported positive interim data from its lead investigational drug in an ongoing Phase 1 study of BHV-1300: The Company reported dose-dependent and rapid IgG reductions in ...

Positive

Seeking Alpha

●

about 2 months ago

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032. Preclinical model testing showed that myostatin inhibitor taldefgrobep alfa + GLP-1 inhibitor was able to show greater reductions in body weight ...

Positive

InvestorPlace

●

3 months ago

The 3 Smartest Healthcare Stocks to Buy With $1K Right Now

Healthcare stocks to buy have been off to the races recently — especially the ones in the weight-loss drug market. Indeed, the market is huge and could entail considerable growth for many years into the future.

More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office	Virgin Islands, British
CEO	Vladimir Coric
Employees	239
Founded	2022
Website	www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now